Literature DB >> 9431385

Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature.

M S Ferreira1, S de A Nishioka, M T Silvestre, A S Borges, F R Nunes-Araújo, A Rocha.   

Abstract

Three new cases of reactivation of Chagas' disease in patients with AIDS, with central nervous system and/or cardiac involvement, are reported. One patient had histological evidence of acute esophageal and gastric Trypanosoma cruzi myositis, a previously unrecognized finding in patients with reactivated Chagas' disease. The patients had a low CD4 lymphocyte count and had other AIDS-defining opportunistic infections. One patient's condition improved with benznidazole therapy. Analysis of these three cases and review of the 13 others published in the literature revealed that the central nervous system is the most commonly involved site (75%), followed by the heart (44%). Early diagnosis and treatment with benznidazole or nifurtimox probably improve the survival rate. Long-term secondary prophylaxis should be recommended for patients who respond to therapy, although it is uncertain which drug to use for this purpose. T. cruzi should be included in the list of opportunistic pathogens causing infection in severely immunocompromised patients with AIDS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9431385     DOI: 10.1086/516130

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease.

Authors:  Walderez Ornelas Dutra; Cristiane Alves Silva Menezes; Fernanda Nobre Amaral Villani; Germano Carneiro da Costa; Alexandre Barcelos Morais da Silveira; Débora d'Avila Reis; Kenneth J Gollob
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

Review 2.  Parasitic infections and myositis.

Authors:  Samar N El-Beshbishi; Nairmen N Ahmed; Samar H Mostafa; Goman A El-Ganainy
Journal:  Parasitol Res       Date:  2011-09-01       Impact factor: 2.289

3.  Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Authors:  Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 4.  Tissue Parasites in HIV Infection.

Authors:  Eva H Clark; Jose A Serpa
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

Review 5.  Parasitic central nervous system infections in immunocompromised hosts.

Authors:  Melanie Walker; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-03-02       Impact factor: 9.079

Review 6.  Trypanosoma cruzi and Chagas' Disease in the United States.

Authors:  Caryn Bern; Sonia Kjos; Michael J Yabsley; Susan P Montgomery
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

Review 7.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 8.  Trypanosoma cruzi infection: a review with emphasis on cutaneous manifestations.

Authors:  Vagish Hemmige; Herbert Tanowitz; Aisha Sethi
Journal:  Int J Dermatol       Date:  2012-05       Impact factor: 2.736

Review 9.  Bacterial, fungal, parasitic, and viral myositis.

Authors:  Nancy F Crum-Cianflone
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

10.  CHAGASIC MENINGOENCEPHALITIS IN AN HIV INFECTED PATIENT WITH MODERATE IMMUNOSUPPRESSION: PROLONGED SURVIVAL AND CHALLENGES IN THE HAART ERA.

Authors:  Renata Buccheri; Maria José Kassab; Vera Lucia Teixeira de Freitas; Sheila Cristina Vicente da Silva; Rita C Bezerra; Zarifa Khoury; Maria Aparecida Shikanai-Yasuda; José E Vidal
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-12       Impact factor: 1.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.